Original clinical investigation

Effect of PlA1/A2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stenting

Claire Le Hello¹ , Rémy Morello² , Agnès Lequerrec³ , Christine Duarte⁴ , John Riddell⁴ and Martial Hamon^4,5

¹Department of Vascular Surgery, Caen Universitary Hospital, Avenue de la Côte de Nacre, 14033 Caen Cedex, France

²Department of Biostatistics, Caen Universitary Hospital, Avenue Georges Clémenceau, 14 000 Caen Cedex, France

³Department of Haemostasis, Caen Universitary Hospital, Avenue de la Côte de Nacre, 14033 Caen Cedex, France

⁴Department of Cardiology, Caen Universitary Hospital, Avenue de la Côte de Nacre, 14033 Caen Cedex, France

⁵INSERM 744, Institut Pasteur de Lille, Lille, France

author email corresponding author email

Thrombosis Journal 2007, 5:19doi:10.1186/1477-9560-5-19

Published:	16 November 2007

Abstract

Aim

To prospectively determine the role of platelet glycoprotein IIIa (GP IIIa) gene PlA1/PlA2 polymorphism on the long-term clinical outcome in patients with coronary artery disease undergoing coronary stenting.

Design and setting

Prospective observational study in the University Hospital of Caen (France).

Patients and methods

1 111 symptomatic consecutive Caucasian patients treated with percutaneous coronary intervention including stent implantation underwent genotyping for GP IIIa PlA1/A2.

Main outcome measures

Long-term clinical outcome in terms of the rate of major adverse cardiac events (MACE, ie death from any cause, non-fatal Q wave or non Q wave myocardial infarction, and need for coronary revascularisation) was obtained and subsequently stratified according to the GP IIIa PlA1/A2 polymorphism.

Results

Three groups of patients were determined according to the GP IIIa PlA1/A2 polymorphism (71.6% had the A1/A1, 25.8% had the A1/A2 and 2.6% had the A2/A2 genotype). These three groups were comparable for all clinical characteristics including sex ratio, mean age, vascular risk factors, previous coronary events, baseline angiographic exam, indication for the percutaneous coronary intervention and drug therapy). The incidence of MACE was similar in these 3 groups of patients during a mean follow-up period of 654+/-152 days. Independent risk factors for MACE were a left ventricular ejection fraction < 40%, absence of treatment with a beta-blocker and absence of treatment with an angiotensin converting enzyme inhibitor during follow-up.

Conclusion

The GP IIIa PlA1/A2 polymorphism does not influence the clinical long-term outcome in patients with symptomatic coronary disease undergoing percutaneous coronary intervention with stent implantation.